Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), dupilumab vs placebo significantly reduced asthma exacerbation rates (AER) and improved...

Full description

Saved in:
Bibliographic Details
Published in:Journal of asthma and allergy 2023-01, Vol.16, p.249-260
Main Authors: Corren, Jonathan, Jackson, David J, Casale, Thomas B, Borish, Larry, Rabe, Klaus F, Busse, William W, Maspero, Jorge F, Jackson, Daniel J, Daizadeh, Nadia, Altincatal, Arman, Radwan, Amr, Khodzhayev, Angela, Djandji, Michel, Jacob-Nara, Juby A, Rowe, Paul J, Deniz, Yamo
Format: Article
Language:English
Subjects:
Age
Allergens
allergic asthma
Allergies
Asthma
Biomarkers
Bronchodilators
Care and treatment
Clinical trials
Cytokines
dupilumab
Genotype & phenotype
Immunoglobulin E
Inflammation
Interleukins
Leukocytes (eosinophilic)
Medical research
Medicine, Experimental
Monoclonal antibodies
Nitric oxide
Original Research
Patient safety
Patients
perennial aeroallergen
Pharmaceutical industry
Phenotypes
Placebos
type 2 asthma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), dupilumab vs placebo significantly reduced asthma exacerbation rates (AER) and improved pre-bronchodilator forced expiratory volume in 1 second (FEV ) in patients with uncontrolled, moderate-to-severe asthma, with greater effects in patients with elevated T2 biomarkers (≥150 eosinophils/µL or fractional exhaled nitric oxide [FeNO] ≥25 parts per billion). Overall safety was consistent with the known dupilumab safety profile. This post hoc analysis assessed dupilumab efficacy in QUEST patients with T2 asthma with evidence of an allergic phenotype (baseline serum IgE ≥30 IU/mL and aeroallergen-specific IgE ≥0.35 IU/mL) by number of aeroallergen sensitizations: 1, 2, 3, or ≥4. Non-sensitized patients (serum total IgE
ISSN:1178-6965
1178-6965
DOI:10.2147/JAA.S385645